Quince Therapeutics, Inc. (QNCX)
(Delayed Data from NSDQ)
$1.68 USD
+0.02 (1.20%)
Updated Nov 12, 2024 04:00 PM ET
After-Market: $1.69 +0.01 (0.60%) 4:38 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
QNCX 1.68 +0.02(1.20%)
Will QNCX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for QNCX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for QNCX
The Zacks Analyst Blog Highlights Quince Therapeutics and XBiotech
Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma
QNCX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for QNCX
Quince Therapeutics presents data from prior Phase 3 ATTeST clinical trial
Quince Therapeutics presents data from prior Phase 3 ATTeST clinical trial
Quince Therapeutics presents safety data from ATTeST trial at CNS meeting
Quince Therapeutics presents safety data from ATTeST trial at CNS meeting
Quince Therapeutics initiated with bullish view at Maxim